Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Integrating genome-wide association studies and gene expression data highlights dysregulated multiple sclerosis risk pathways.
Making Treatment & Lifestyle Decisions: Thinking About Benefits & Risks
Long-term disability and prognostic factors in polyneuropathy associated with anti-myelin- associated glycoprotein (MAG) antibodies.
Comparing Characteristics of Hungarian "Real Life" Patients With Participants of RCTS: First-Line Disease Modifying Therapies in Multiple Sclerosis.
Cryopreserved vitamin D3-tolerogenic dendritic cells pulsed with autoantigens as a potential therapy for multiple sclerosis patients.
Persistence with Fingolimod Versus Dimethyl Fumarate in Patients with Multiple Sclerosis: Retrospective Analysis of us Open-Source Pharmacy Data.
Voxel Based Morphometry in Optical Coherence Tomography: Validation & Core Findings.
MS Research Roundup: December 21, 2014
Regression-Based Norms for the Brief Visuospatial Memory Test-Revised in Italian population and application in MS patients.
Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus.
American Society for Neurochemistry 2014
Characteristics of Patients with Relapsing Remitting Multiple Sclerosis Taking Injectable and Oral Disease Modifying Treatments in the United States.
Persistence in Open and Closed Data Sources: A Study of Fingolimod Verse Interferons/Glatiramer Acetate in Patients with Multiple Sclerosis.
Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort: JC virus seroprevalence in Spain.
Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatment.
Histopathological comparison of Kearns-Sayre syndrome and PGC-1α-deficient mice suggests a novel concept for vacuole formation in mitochondrial encephalopathy.
Case Report of Lewis and Sumner Syndrome with Bilateral Vagus Nerves Paralysis for 16 Years.
High-throughput platforms for the screening of new therapeutic targets for neurodegenerative diseases.
ANNALS EXPRESS: Multiple Sclerosis: Assay of Free Immunoglobulin Light Chains.
Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial.
Host cell virus entry mechanisms enhance anti-JCV-antibody switch in natalizumab-treated multiple sclerosis patients.
Demyelinating Guillain-Barré syndrome recurs more frequently than axonal subtypes.
Switching from natalizumab to fingolimod: an observational study.
Partnership and consent in MS treatment choice.
PEGylated Interferon May Boost Efficacy, Reduce Side Effects

Pages